Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00009698 · ClinicalTrials.gov registry record · Phase 1
Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia
A Phase 1 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00009698 is a Phase 1 study that has completed, run by Children's Oncology Group. The registered enrollment target is 1 participants.
The verdict
NCT00009698, a Phase 1 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 in treating children who have undergone bone marrow transplantation for acute myeloid leukemia.
Interventions
- BIOLOGICAL aldesleukin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 1998-03 |
| Est. Completion | 2005-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00009698
The ClinicalTrials.gov registry entry for NCT00009698 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aldesleukin is the first listed.
NCT00009698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00009698 about?
NCT00009698 is a clinical study titled "Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia". RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 in treating children who have undergone bone marrow transplantation for acute myeloid leukemia.
What is the current status of trial NCT00009698?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 1998-03. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00009698?
The interventions under investigation include: aldesleukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00009698?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.